Alprazolam ER is an anti-anxiety Schedule-IV controlled substance indicated for the treatment of panic disorder with or without agoraphobia.  It is an AB-rated, therapeutically equivalent alternative to the brand, Xanax® XR (a trademark of The Upjohn Company).  Amneal received U.S. FDA approval to manufacture Alprazolam ER as a result of acquiring Interpharm’s strong product line last year.  The Amneal generic is available in a 60-count size for all strengths, which began shipping June 2009.

Amneal has also been granted FDA approval to manufacture Benazepril HCl.  Benazepril HCl is an AB-rated, bioequivalent alternative to the brand, Lotensin® (a trademark of Ciba-Geigy), and is indicated for the treatment of hypertension.  All four strengths of the generic are available in 100- and 500-count sizes, also began shipping June 2009.

“The introduction of Alprazolam ER and Benazepril HCI supports Amneal’s growth strategy of adding diverse, more sophisticated lines such as modified release medications, controlled substances and hormonal products,” said Jim Luce, Amneal Executive Vice President, Sales & Marketing.  He continued, “Amneal’s rapidly expanding portfolio of high quality products and dedication to customer service are enabling us to develop a significant presence in the generic prescription marketplace.”